Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1245
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1225–1236 of 1,245 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

NCT02661451
Site status not listed — check the official record
Conditions
Aortic Valve Stenosis
Interventions
SAPIEN 3 THV, Optimal Heart Failure Therapy
Device · Biological
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
46
States / cities
Chandler, Arizona • La Jolla, California • Los Angeles, California + 37 more
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Conditions
Shortness of Breath
Interventions
Caption LungAI
Device
Lead sponsor
Caption Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Greensboro, North Carolina
Active, not recruiting Phase 1Phase 2 Interventional

A Study of NDI 1150-101 in Patients With Solid Tumors

NCT05128487
Site status not listed — check the official record
Conditions
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
Interventions
NDI-101150, Pembrolizumab
Drug
Lead sponsor
Nimbus Saturn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
19
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more
Recruiting Phase 1Phase 2 Interventional

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042
Status at this site: Recruiting
Conditions
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
Biological
Lead sponsor
Simcha IL-18, Inc.
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more
Active, not recruiting Phase 1Phase 2 Interventional

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

NCT04598919
Site status not listed — check the official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Saracatinab, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Denver, Colorado • New Haven, Connecticut • New York, New York + 1 more
Recruiting Phase 2Phase 3 Interventional

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171
Status at this site: Recruiting
Conditions
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Interventions
SBP-101, Nab-paclitaxel, Gemcitabine, Placebo
Drug · Other
Lead sponsor
Panbela Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Hot Springs, Arkansas • Fullerton, California • New Haven, Connecticut + 11 more
Active, not recruiting Not applicable Interventional Results available

Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma

NCT03422003
Site status not listed — check the official record
Conditions
Breast Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
15
States / cities
San Francisco, California • Stanford, California • Edwards, Colorado + 10 more
Recruiting Not applicable Interventional

The DRAGON 2 Trial

NCT05428735
Status at this site: Recruiting
Conditions
Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
Interventions
Embolization
Procedure
Lead sponsor
Maastricht University
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting No phase listed Observational

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

NCT03827694
Status at this site: Recruiting
Conditions
Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
Interventions
Non-Invasive Testing for PIFI
Diagnostic Test
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
120 Days to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
32
States / cities
Little Rock, Arkansas • La Jolla, California • Orange, California + 28 more
Conditions
Moderate to Severe Asthma
Interventions
Dupilumab, Benralizumab
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Active, not recruiting No phase listed Observational

The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)

NCT04091984
Site status not listed — check the official record
Conditions
Kidney Transplant Rejection
Interventions
Prospera
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.